Compare immunoadsorption vs plasma exchange for Guillain-Barré
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether immunoadsorption works as well as plasma exchange to improve symptoms in people with Guillain-Barré syndrome. The goal is to find which treatment helps recovery and is safer for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Guillain-Barré syndrome (GBS) based on standard medical criteria
- You must be 18 years old or older
- You should not have a clear ongoing body-wide infection (by symptoms or lab tests like high C-reactive protein or a nitrite-positive urine infection)
- You should not have taken an ACE inhibitor blood pressure/heart medicine within 1 week before starting treatment
- You must not have other reasons you cannot safely receive immunoadsorption or plasma exchange
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that looks at people who were suspected to have Guillain-Barré syndrome and were cared for at University Hospital of Basel in the past. It does not test a new treatment—researchers review existing care to learn more about this condition.
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
This study compares immunoadsorption (a blood-filtering treatment) versus intravenous immunoglobulin (IVIG) to see which works better and is safer for Guillain-Barré syndrome. It may help you by testing treatments commonly used to reduce nerve damage and improve recovery.
This trial tests if the drug efgartigimod can help people with Guillain-Barré Syndrome (GBS). If you have had GBS symptoms for less than two weeks and your weakness is moderate to severe, this study may be an option.
This trial studies whether an inpatient rehabilitation program can help people with Guillain-Barré syndrome. It may be useful if you need structured therapy and support during recovery.
Hear when a new GBS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.